Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for Refractory ITP
NCT03013114Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in immune thrombocytopenia (ITP), sponsored by Shandong University. Primary endpoint: Platelet counts at 3 months. Status: unknown.
02
Drugs
bortezomib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03013114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013114.